Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CCR8 | P51685 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12472388 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471022 | 0.97 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471430 | 0.97 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL17053647 | 0.93 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471514 | 0.92 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471205 | 0.92 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471201 | 0.92 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471506 | 0.92 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12687661 | 0.92 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 | |
| SCHEMBL12471899 | 0.91 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2MAPTCCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2672823-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
| EP-2672823-A1 | S1P MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | KDM4E 3037/4885ALDH1A1 2452/4885SMN1; SMN2 3024/4885 |
| US-20140371209-A1 | S1P Modulating Agents | S1PR2, S1PR1, S1PR3 | KDM4E 3804/4885ALDH1A1 2436/4885SMN1; SMN2 1805/4885 |
| US-10406144-B2 | SIP modulating agents | S1PR2, S1PR1, S1PR3 | KDM4E 3487/4885ALDH1A1 2802/4885SMN1; SMN2 1975/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | KDM4E 2656/4885ALDH1A1 2508/4885SMN1; SMN2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.